Fund Holdings — Lion Point Capital, LP

Total Portfolio Value:
$24.93M
Total Bought:
$3.20M
Total Sold:
$10.39M
Net Transaction:
-$7.19M
Notable People:
Carl Didric Marcus Cederholm
Securities
▲▼
SharesValue
Q2 2024
▲▼
Q3 2024
▲▼
Change
▲▼
Q2 2024
▲▼
Q3 2024
▲▼
Weight (%)
▲▼
Change
▲▼
Insmed Incorporated(INSM)70,33552,200-18,135$4.71M$3.81M15.29%-$901.8K
Geron Corporation(GERN)630,000630,0000$2.67M$2.86M11.47%+$189.0K
Ardelyx Inc856,667370,000-486,667$6.35M$2.55M10.23%-$3.80M
Milestone Pharmaceuticals Inc.(MIST)2,340,2071,654,154-686,053$3.09M$2.51M10.09%-$574.8K
Biohaven Ltd.(BHVN)035,400+35,400$0$1.77M7.10%+$1.77M
Kiniksa Pharmaceuticals International, plcCL A(KNSA)104,69161,400-43,291$1.95M$1.53M6.16%-$420.2K
BridgeBio Pharma, Inc.(BBIO)49,00049,0000$1.24M$1.25M5.00%+$6.4K
Marinus Pharmaceuticals Inc2,114,827693,778-1,421,049$2.47M$1.22M4.90%-$1.25M
Fennec Pharmaceuticals Inc.(FENC)170,000215,000+45,000$1.04M$1.07M4.31%+$36.3K
Mineralys Therapeutics, Inc.(MLYS)79,00079,0000$924.3K$956.7K3.84%+$32.4K
Syndax Pharmaceuticals, Inc.(SNDX)65,00046,200-18,800$1.33M$889.4K3.57%-$445.1K
Avadel Pharmaceuticals Plc82,50064,000-18,500$1.16M$839.4K3.37%-$320.6K
Bluebird Bio Inc678,2561,578,256+900,000$667.5K$819.9K3.29%+$152.4K
REGENXBIO Inc.(RGNX)36,25057,750+21,500$424.1K$605.8K2.43%+$181.7K
Jasper Therapeutics, Inc.(JSPR)32,00032,0000$726.4K$601.9K2.41%-$124.5K
Disc Medicine, Inc.(IRON)07,700+7,700$0$378.4K1.52%+$378.4K
Benitec Biopharma Inc.(BNTC)039,000+39,000$0$358.4K1.44%+$358.4K
Arcutis Biotherapeutics, Inc.(ARQT)035,100+35,100$0$326.4K1.31%+$326.4K
Seres Therapeutics, Inc.(MCRB)340,761340,7610$246.6K$322.4K1.29%+$75.8K
Lumos Pharma Inc90,79439,589-51,205$210.6K$153.2K0.61%-$57.4K
Microsoft Corporation(MSFT)1001000$44.7K$43.0K0.17%-$1.7K
Spruce Biosciences Inc75,00075,0000$38.8K$35.6K0.14%-$3.2K
Alphabet Inc.CL C(GOOG)1001000$18.3K$16.7K0.07%-$1.6K
Battalion Oil Corporation(BATL)7,4230-7,423$24.8K$0—-$24.8K
Burgerfi International Inc2,745,9380-2,745,938$557.4K$0—-$557.4K
Burgerfi International IncW EXP 12 16 2022,083,4380-2,083,438$26.3K$0—-$26.3K
Enphys Acquisition CorpCL A78,1250-78,125$857.8K$0—-$857.8K
Neurocrine Biosciences, Inc.(NBIX)8,3500-8,350$1.15M$0—-$1.15M
Page 1 of 1
Lion Point Capital, LP — 13F Holdings — Q3 2024 | TickerTrail